Vitamin D supplementation for prevention of cancer in adults

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 6, 2014, Pages

  Bjelakovic, Goran ^a,b   Gluud, Lise Lotte ^c   Nikolova, Dimitrinka ^b   Whitfield, Kate ^b   Krstic, Goran ^d   Wetterslev, Jørn ^b   Gluud, Christian ^b  

^a UNIVERSITY OF NI   (Serbia)

^b Rigshospitalet   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d FRASER HEALTH AUTHORITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; VITAMIN D; 1,25-DIHYDROXYVITAMIN D; HYDROXYCOLECALCIFEROL; VITAMIN;

ADULT; ADVERSE EVENT; ALL CAUSE MORTALITY; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; COST BENEFIT ANALYSIS; ESOPHAGUS CANCER; HUMAN; LIVER CANCER; LUNG CANCER; MALIGNANT NEOPLASM; NEPHROLITHIASIS; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PATIENT DROPOUT; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SECONDARY PREVENTION; STOMACH CANCER; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; UTERUS CANCER; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; AGED; ANALOGS AND DERIVATIVES; DIET SUPPLEMENTATION; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; NEOPLASMS;

AGED; CALCITRIOL; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; MALE; MIDDLE AGED; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN D; VITAMINS;

EID: 84911432007     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007469.pub2     Document Type: Article

References (251)

1. Alexander C. Prevention of low-trauma fractures in older people. Lancet 2005;366(9485):544.
2. Avenell A, Cook JA, Maclennan GS, Macpherson GC. Vitamin D supplementation to prevent infections: a sub-study of a randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age and Ageing 2007;36(5):574-7.
3. Avenell A, MacLennan GS, Jenkinson DJ, McPherson GC, McDonald AM, Pant PR, et al.Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trial). Journal of Clinical Endocrinology and Metabolism 2012;97(2):614-22.
4. Cameron ID, Kurrle SE. Prevention of low-trauma fractures in older people. Lancet 2005;366(9485):543.
5. Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC, et al.Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005;365(9471):1621-8.
6. McDonald A, Ross S, Campbell M, the RECORD Study Group. Delivering clinical trial supplies by post to elderly trial participants: a feasibility study. Applied Clinical Trials 2004;Feb:58-9.
7. Sambrook P. Vitamin D and fractures: quo vadis. Lancet 2005;365(9471):1599-600.
8. Scharla S. Prevention of low-trauma fractures in older people. Lancet 2005;366(9485):543.
9. Bolton-Smith C, McMurdo ME, Paterson CR, Mole PA, Harvey JM, Fenton ST, et al.Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women. Journal of Bone and Mineral Research 2007;22(4):509-19.
10. Brunner RL, Cochrane B, Jackson RD, Larson J, Lewis C, Limacher M, et al.Calcium, vitamin D supplementation, and physical function in the Women's Health Initiative. Journal of the American Dietetic Association 2008;108(9):1472-9.
11. Brunner RL, Wactawski-Wende J, Caan BJ, Cochrane BB, Chlebowski RT, Gass ML, et al.The effect of calcium plus vitamin D on risk for invasive cancer: results of the Women's Health Initiative (WHI) calcium plus vitamin D randomized clinical trial. Nutrition and Cancer 2011;63(6):827-41.
12. Caan B, Neuhouser M, Aragaki A, Lewis CB, Jackson R, LeBoff MS. Calcium plus vitamin D supplementation and the risk of postmenopausal weight gain. Archives of Internal Medicine 2007;167(9):893-902.
13. Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, et al.Calcium plus vitamin D supplementation and the risk of breast cancer. Journal of the National Cancer Institute 2008;100(22):1581-91.
14. De Boer IH, Tinker LF, Connelly S, Curb JD, Howard BV, Kestenbaum B, et al.Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care 2008;31(4):701-7.
15. Ding EL, Mehta S, Fawzi WW, Giovannucci EL. Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial. International Journal of Cancer 2008;122(8):1690-4.
16. Hsia J, Heiss G, Ren H, Allison M, Dolan NC, Greenland P, et al.Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007;115(7):846-54.
17. Jackson RD, LaCroix AZ, Cauley JA, McGowan J. The Women's Health Initiative calcium-vitamin D trial: overview and baseline characteristics of participants. Annals of Epidemiology 2003;13(9 Suppl):S98-106.
18. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al.Calcium plus vitamin D supplementation and the risk of fractures. New England Journal of Medicine 2006;354(7):669-83.
19. Jackson RD, Shidham S. The role of hormone therapy and calcium plus vitamin D for reduction of bone loss and risk for fractures: lessons learned from the Women's Health Initiative. Current Osteoporosis Reports 2007;5(4):153-9.
20. Jackson RD, Wright NC, Beck TJ, Sherrill D, Cauley JA, Lewis CE, et al.Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International 2011;88(3):198-208.
21. Manson JE, Allison MA, Carr JJ, Langer RD, Cochrane BB, Hendrix SL, et al.Calcium/vitamin D supplementation and coronary artery calcification in the Women's Health Initiative. Menopause 2010;17(4):683-91.
22. Margolis KL, Ray RM, Van Horn L, Manson JE, Allison MA, Black HR, et al.Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. Hypertension 2008;52(5):847-55.
23. Prentice RL, Anderson GL. The women's health initiative: lessons learned. Annual Review of Public Health 2008;29:131-50.
24. Rajpathak SN, Xue X, Wassertheil-Smoller S, Van Horn L, Robinson JG, Liu S, et al.Effect of 5 y of calcium plus vitamin D supplementation on change in circulating lipids: results from the Women's Health Initiative. American Journal of Clinical Nutrition 2010;91(4):894-9.
25. Rohan TE, Negassa A, Chlebowski RT, Ceria-Ulep CD, Cochrane BB, Lane DS, et al.A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease. Breast Cancer Research and Treatment 2009;116(2):339-50.
26. Tang JY, Fu T, Leblanc E, Manson JE, Feldman D, Linos E, et al.Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial. Journal of Clinical Oncology 2011;29(22):3078-84.
27. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials 1998;19(1):61-109.
28. Twombly R. Negative Women's Health Initiative findings stir consternation, debate among researchers. Journal of the National Cancer Institute 2006;98(8):508-10.
29. Wallace RB, Wactawski-Wende J, O'Sullivan MJ, Larson JC, Cochrane B, Gass M, et al.Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements. American Journal of Clinical Nutrition 2011;94(1):270-7.
30. Wittes J, Barrett-Connor E, Braunwald E, Chesney M, Cohen HJ, Demets D, et al.Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board. Clinical Trials 2007;4(3):218-34.
31. Daly RM, Bass S, Nowson C. Long-term effects of calcium-vitamin-D3-fortified milk on bone geometry and strength in older men. Bone 2006;39(4):946-53.
32. Daly RM, Brown M, Bass S, Kukuljan S, Nowson C. Calcium- and vitamin D3-fortified milk reduces bone loss at clinically relevant skeletal sites in older men: a 2-year randomized controlled trial. Journal of Bone and Mineral Research 2006;21(3):397-405.
33. Daly RM, Petrass N, Bass S, Nowson CA. The skeletal benefits of calcium- and vitamin D3-fortified milk are sustained in older men after withdrawal of supplementation: an 18-mo follow-up study. American Journal of Clinical Nutrition 2008;87(3):771-7.
34. Gallagher JC. The effects of calcitriol on falls and fractures and physical performance tests. Journal of Steroid Biochemistry and Molecular Biology 2004;89-90(1-5):497-501.
35. Gallagher JC, Fowler SE, Detter JR, Sherman SS. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. Journal of Clinical Endocrinology and Metabolism 2001;86(8):3618-28.
36. Gallagher JC, Rapuri PB, Haynatzki G, Detter JR. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. Journal of Clinical Endocrinology and Metabolism 2002;87(11):4914-23.
37. Rapuri PB, Gallagher JC, Haynatzki G. Effect of vitamins D2 and D3 supplement use on serum 25OHD concentration in elderly women in summer and winter. Calcified Tissue International 2004;74(2):150-6.
38. Sai AJ, Gallagher JC, Fang X. Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor-α genotypes. Menopause 2011;18(10):1101-12.
39. Glendenning P, Zhu K, Inderjeeth C, Howat P, Lewis JR, Prince RL. Effects of three monthly oral 150, 000 IU cholecalciferol supplementation on falls, mobility and muscle strength in older postmenopausal women: a randomised controlled trial. Journal of Bone and Mineral Research 2012;27(1):170-6.
40. Grady D, Halloran B, Cummings S, Leveille S, Wells L, Black D, et al.1, 25-Dihydroxyvitamin D3 and muscle strength in the elderly: a randomized controlled trial. Journal of Endocrinology and Metabolism 1991;73(5):1111-7.
41. Janssen HC, Samson MM, Verhaar HJ. Muscle strength and mobility in vitamin D-insufficient female geriatric patients: a randomized controlled trial on vitamin D and calcium supplementation. Aging Clinical an Experimental Research 2010;22(1):78-84.
42. Heikkinen AM, Niskanen L, Ylä-Herttuala S, Luoma J, Tuppurainen MT, Komulainen M, et al.Postmenopausal hormone replacement therapy and autoantibodies against oxidized LDL. Maturitas 1998;29(2):155-61.
43. Heikkinen AM, Parviainen M, Niskanen L, Komulainen M, Tuppurainen MT, Kröger H, et al.Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study. Journal of Clinical Endocrinology and Metabolism 1997;82(8):2476-82.
44. Heikkinen AM, Tuppurainen MT, Niskanen L, Komulainen M, Penttilä I, Saarikoski S, et al.Long-term vitamin D3 supplementation may have adverse effects on serum lipids during postmenopausal hormone replacement therapy. European Journal of Endocrinology / European Federation of Endocrine Societies 1997;137(5):495-502.
45. Komulainen M, Kröger H, Tuppurainen MT, Heikkinen AM, Alhava E, Honkanen R, et al.Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial. Journal of Clinical Endocrinology and Metabolism 1999;84(2):546-52.
46. Komulainen M, Kröger H, Tuppurainen MT, Heikkinen AM, Honkanen R, Saarikoski S. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial. Osteoporosis International 2000;11(3):211-8.
47. Komulainen M, Tuppurainen MT, Kröger H, Heikkinen AM, Puntila E, Alhava E, et al.Vitamin D and HRT: no benefit additional to that of HRT alone in prevention of bone loss in early postmenopausal women. A 2.5-year randomized placebo-controlled study. Osteoporosis International 1997;7(2):126-32.
48. Komulainen MH, Kröger H, Tuppurainen MT, Heikkinen AM, Alhava E, Honkanen R, et al.HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas 1998;31(1):45-54.
49. Salmen T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Pallonen H, et al.Relation of aromatase gene polymorphism and hormone replacement therapy to serum estradiol levels, bone mineral density, and fracture risk in early postmenopausal women. Annals of Medicine 2003;35(4):282-8.
50. Salmén T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Pallonen H, et al.Relation of androgen receptor gene polymorphism to bone mineral density and fracture risk in early postmenopausal women during a 5-year randomized hormone replacement therapy trial. Journal of Bone and Mineral Research 2003;18(2):319-24.
51. Salmén T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Saarikoski S, et al.Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy. Journal of Bone and Mineral Research 2000;15(2):315-21.
52. Salmén T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Saarikoski S, et al.Relation of estrogen receptor-alpha gene polymorphism and hormone replacement therapy to fall risk and muscle strength in early postmenopausal women. Annals of Medicine 2002;34(1):64-72.
53. Salmén T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Saarikoski S, et al.The protective effect of hormone-replacement therapy on fracture risk is modulated by estrogen receptor alpha genotype in early postmenopausal women. Journal of Bone and Mineral Research 2000;15(12):2479-86.
54. Tuppurainen M, Heikkinen AM, Penttilä I, Saarikoski S. Does vitamin D3 have negative effects on serum levels of lipids? A follow-up study with a sequential combination of estradiol valerate and cyproterone acetate and/or vitamin D3. Maturitas 1995;22(1):55-61.
55. Tuppurainen MT, Komulainen M, Kröger H, Honkanen R, Jurvelin J, Puntila E, et al.Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen. Osteoporosis International 1998;8(1):32-8.
56. Bolland MJ, Reid IR. Calcium supplementation and cancer incidence. American Journal of Clinical Nutrition 2008;87(3):792-3.
57. Lappe JM, Davies KM, Travers-Gustafson D, Heaney RP. Vitamin D status in a rural postmenopausal female population. Journal of the American College of Nutrition 2006;25(5):395-402.
58. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. American Journal of Clinical Nutrition 2007;85(6):1586-91.
59. Ojha RP, Felini MJ, Fischbach LA. Vitamin D for cancer prevention: valid assertion or premature anointment. American Journal of Clinical Nutrition 2007;86(6):1804-5.
60. Schabas R. Artifact in the control group undermines the conclusions of a vitamin D and cancer study. American Journal of Clinical Nutrition 2008;87(3):792.
61. Sood MM, Sood AR. Dietary vitamin D and decreases in cancer rates: Canada as the national experiment. American Journal of Clinical Nutrition 2007;86(5):1549.
62. Larsen T, Mose FH, Bech JN, Hansen AB, Pedersen EB. Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial. American Journal of Hypertension 2012;25(11):1215-22.
63. Murdoch DR, Slow S, Chambers ST, Jennings LC, Stewart AW, Priest PC, et al.Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA 2012;308(13):1333-9.
64. Ott SM, Chesnut CH 3rd. Calcitriol treatment is not effective in postmenopausal osteoporosis. Annals of Internal Medicine 1989;110(4):267-74.
65. Prince RL, Austin N, Devine A, Dick IM, Bruce D, Zhu K. Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Archives of Internal Medicine 2008;168(1):103-8.
66. Zhu K, Bruce D, Austin N, Devine A, Ebeling PR, Prince RL. Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. Journal of Bone and Mineral Research 2008;23(8):1343-8.
67. Sanders KM, Stuart AL, Merriman EN, Read ML, Kotowicz MA, Young D, et al.Trials and tribulations of recruiting 2, 000 older women onto a clinical trial investigating falls and fractures: Vital D study. BMC Medical Research Methodology 2009;9:78.
68. Sanders KM, Stuart AL, Williamson EJ, Jacka FN, Dodd S, Nicholson G, et al.Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. British Journal of Psychiatry 2011;198(5):357-64.
69. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, et al.Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010;303(18):1815-22.
70. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326(7387):469.
71. Witham MD, Price RJ, Struthers AD, Donnan PT, Messow CM, Ford I, et al.Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. JAMA Internal Medicine 2013;173(18):1672-9.
72. Macdonald HM, Wood AD, Aucott LS, Black AJ, Fraser WD, Mavroeidi A, et al.Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: a 1-year double-blind RCT in postmenopausal women. Journal of Bone and Mineral Research 2013;28(10):2202-13.
73. Wood AD, Secombes KR, Thies F, Aucott L, Black AJ, Mavroeidi A, et al.Vitamin D3 supplementation has no effect on conventional cardiovascular risk factors: a parallel-group, double-blind, placebo-controlled RCT. Journal of Clinical Endocrinology and Metabolism 2012;98(11):4507-15.
74. Wood AD, Secombes KR, Thies F, Aucott LS, Black AJ, Reid DM, et al.A parallel group double-blind RCT of vitamin D3 assessing physical function: is the biochemical response to treatment affected by overweight and obesity. Osteoporosis International 2014;25(1):305-15.
75. Anderson LN, Cotterchio M, Vieth R, Knight JA. Vitamin D and calcium intakes and breast cancer risk in pre- and postmenopausal women. American Journal of Clinical Nutrition 2010;91(6):1699-707.
76. Chadha MK, Tian L, Mashtare T, Payne V, Silliman C, Levine E, et al.Phase 2 trial of weekly intravenous 1, 25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer 2010;116(9):2132-9.
77. Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, Dworakowski E, et al.Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prevention Research 2009;2(6):598-604.
78. Diamond T, Wong YK, Golombick T. Effect of oral cholecalciferol 2, 000 versus 5, 000 IU on serum vitamin D, PTH, bone and muscle strength in patients with vitamin D deficiency. Osteoporosis International 2013;24(3):1101-5.
79. Ahearn TU, McCullough ML, Flanders WD, Long Q, Sidelnikov E, Fedirko V, et al.A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on markers of their metabolism in normal mucosa of colorectal adenoma patients. Cancer Research 2011;71(2):413-23.
80. Fedirko V, Bostick RM, Long Q, Flanders WD, McCullough ML, Sidelnikov E, et al.Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial. Cancer Epidemiology, Biomarkers and Prevention 2010;19(1):280-91.
81. McCullough ML, Bostick RM, Daniel CR, Flanders WD, Shaukat A, Davison J, et al.Vitamin D status and impact of vitamin D3 and/or calcium supplementation in a randomized pilot study in the Southeastern United States. Journal of the American College of Nutrition 2009;28(6):678-86.
82. Garland CF, French CB, Baggerly LL, Heaney RP. Vitamin D supplement doses and serum 25-hydroxyvitamin D in the range associated with cancer prevention. Anticancer Research 2011;31(2):607-11.
83. Glossmann H. Vitamin D, UV, and skin cancer in the elderly: to expose or not to expose. Gerontology 2011;57(4):350-3.
84. Herrmann W, Kirsch SH, Kruse V, Eckert R, Gräber S, Geisel J, et al.One year B and D vitamins supplementation improves metabolic bone markers. Clinical Chemistry and Laboratory Medicine 2013;51(3):639-47.
85. Holt PR, Bresalier RS, Ma CK, Liu KF, Lipkin M, Byrd JC, et al.Calcium plus vitamin D alters preneoplastic features of colorectal adenomas and rectal mucosa. Cancer 2006;106(2):287-96.
86. Jacobs ET, Thomson CA, Flatt SW, Al-Delaimy WK, Hibler EA, Jones LA, et al.Vitamin D and breast cancer recurrence in the Women's Healthy Eating and Living (WHEL) Study. American Journal of Clinical Nutrition 2011;93(1):108-17.
87. Kampman E, Slattery ML, Caan B, Potter JD. Calcium, vitamin D, sunshine exposure, dairy products and colon cancer risk (United States). Cancer Causes and Control 2000;11(5):459-66.
88. Lagari VS, Gómez-Marín O, Levis S. Differences in vitamin D3 dosing regimens in a geriatric community-dwelling population. Endocrine Practice 2012;18(6):847-54.
89. Peppone LJ, Huston AJ, Reid ME, Rosier RN, Zakharia Y, Trump DL, et al.The effect of various vitamin D supplementation regimens in breast cancer patients. Breast Cancer Research and Treatment 2011;127(1):171-7.
90. Rheem DS, Baylink DJ, Olafsson S, Jackson CS, Walter MH. Prevention of colorectal cancer with vitamin D. Scandinavian Journal of Gastroenterology 2010;45(7-8):775-84.
91. Tellioglu A, Basaran S, Guzel R, Seydaoglu G. Efficacy and safety of high dose intramuscular or oral cholecalciferol in vitamin D deficient/insufficient elderly. Maturitas 2012;72(4):332-8.
92. Vashi PG, Trukova K, Lammersfeld CA, Braun DP, Gupta D. Impact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology. Nutrition Journal 2010;9:60.
93. Vieth R. How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology. Anticancer Research 2009;29(9):3675-84.
94. Zabihiyeganeh M, Jahed A, Nojomi M. Treatment of hypovitaminosis D with pharmacologic doses of cholecalciferol, oral vs intramuscular; an open labeled RCT. Clinical Endocrinology 2013;78(2):210-6.
95. ACTRN12611000402943. Effect of vitamin D supplementation on cardiovascular and respiratory disease event rates in lder adults, and the incidence of non-vertebral fractures. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336777 (accessed 9th May 2014).
96. ISRCTN17873085. Examining the pleiotropic actions of vitamin D supplementation in patients with chronic heart failure. www.controlled-trials.com/ISRCTN17873085 (accessed 9th May 2014).
97. Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D, et al.The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials 2012;33(1):159-71.
98. NCT00585637. Defining Optimal Doses of Vitamin D for Chemoprevention in Blacks. clinicaltrials.gov/show/NCT00585637 (9th May 2014).
99. NCT00662844. Optimum vitamin D nutrition in young women. clinicaltrials.gov/ct2/show/NCT00662844?term=NCT00662844&rank=1 (accessed 9th May 2014).
100. NCT00784511. Vitamin D, glucose control and insulin sensitivity in African-Americans. clinicaltrials.gov/ct2/show/NCT00784511?term=NCT00784511&rank=1 (accessed 9th May 2014).
101. NCT01052051. Clinical trial of vitamin D3 to reduce cancer risk in postmenopausal women. clinicaltrials.gov/ct2/show/NCT01052051?term=NCT01052051&rank=1 (accessed 9th May 2014).
102. NCT01176344. Does vitamin D supplementation prevent progression of knee osteoarthritis? a randomised controlled trial. clinicaltrials.gov/ct2/show/NCT01176344?term=NCT01176344&rank=1 (accessed 9th May 2014).
103. NCT01463813. Finnish vitamin D trial (FIND). clinicaltrials.gov/ct2/show/NCT01463813?term=NCT01463813&rank=1 (accessed 9th May 2014).
104. NCT00153816. Vitamin D/Calcium Polyp Prevention Study. clinicaltrials.gov/show/NCT00153816 (accessed 9th May 2014).
105. Rees JR, Hendricks K, Barry EL, Peacock JL, Mott LA, Sandler RS, et al.Vitamin D3 supplementation and upper respiratory tract infections in a randomized, controlled trial. Clinical Infectious Diseases 2013;57(10):1384-92.
106. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, et al.Serum vitamin D concentration and prostate cancer risk: a nested case-control study. Journal of the National Cancer Institute 2008;100(11):796-804.
107. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al.GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. Journal of Clinical Epidemiology 2013;66(7):719-25.
108. Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al.GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. Journal of Clinical Epidemiology 2013;66(7):726-35.
109. Apperly FL. The relation of solar radiation to cancer mortality in North American. Cancer Research 1941;1:191-5.
110. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. Journal of Clinical Endocrinology and Metabolism 2004;89(11):5387-91.
111. Autier P, Boniol M, Mullie P. Vitamin D status and ill health: a systematic review. The Lancet Diabetes & Endocrinology 2014;2(1):76-89.
112. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al.GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6. [PUBMED: 21208779]
113. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088-101. [MEDLINE: 7786990]
114. Bikle D. Nonclassic actions of vitamin D. Journal of Clinical Endocrinology and Metabolism 2009;94(1):26-34.
115. Bikle DD. Vitamin D and cancer: the promise not yet fulfilled. Endocrine 2014;46:29-38.
116. Bischoff-Ferrari H. Vitamin D: what is an adequate vitamin D level and how much supplementation is necessary. Best Practice & Research. Clinical Rheumatology 2009;23(6):789-95.
117. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, et al.Vitamin D supplementation for prevention of mortality in adults. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD007470.pub3]
118. Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, et al.Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:c3691.
119. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011;342:d2040. [DOI: 10.1136/bmj.d2040]
120. Bolland MJ, Grey A, Gamble GD, Reid IR. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinology 2014;2(4):307-20.
121. Bouillon R, Van Schoor NM, Gielen E, Boonen S, Mathieu C, Vanderschueren D, et al.Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. The Journal of Clinical Endocrinology and Metabolism 2013;98(8):E1283-304.
122. Bristow SM, Bolland MJ, MacLennan GS, Avenell A, Grey A, Gamble GD, et al.Calcium supplements and cancer risk: a meta-analysis of randomised controlled trials. The British Journal of Nutrition 2013;110(8):1384-93.
123. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61(8):763-9.
124. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98.
125. Brunetti M1, Shemilt I, Pregno S, Vale L, Oxman AD, Lord J, et al.GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. Journal of Clinical Epidemiology 2013;66(2):140-50.
126. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al.SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158(3):200-7.
127. Chen W, Dawsey SM, Qiao YL, Mark SD, Dong ZW, Taylor PR, et al.Prospective study of serum 25(OH)-vitamin D concentration and risk of oesophageal and gastric cancers. British Journal of Cancer 2007;97(1):123-8.
128. Chiang KC, Chen TC. The anti-cancer actions of vitamin D. Anticancer Agents in Medicinal Chemistry 2013;13(1):126-39.
129. Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Annals of Internal Medicine 2011;155(12):827-38.
130. Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, et al.Effectiveness and safety of vitamin D in relation to bone health Effectiveness and safety of vitamin D in relation to bone health. Evidence Report/Technology Assessment 2007;158:1-235. [MEDLINE: 18088161]
131. Cutolo M. Vitamin D and autoimmune rheumatic diseases. Rheumatology 2009;48(3):210-2.
132. Davis CD, Dwyer JT. The "sunshine vitamin": benefits beyond bone?. Journal of the National Cancer Institute 2007;99(21):1563-5. [MEDLINE: 17971523]
133. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporosis International 2005;16(7):713-6.
134. Dawson-Hughes B, Mithal A, Bonjour JP, Boonen S, Burckhardt P, Fuleihan GE, et al.IOF position statement: vitamin D recommendations for older adults. Osteoporosis International 2010;21(7):1151-4.
135. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50. [MEDLINE: 3616287]
136. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. [MEDLINE: 3802833]
137. DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) Group. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 2010;340:b5463.
138. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed) 1997;315(7109):629-34. [MEDLINE: 1997456606]
139. Fleet JC, DeSmet M, Johnson R, Li Y. Vitamin D and cancer: a review of molecular mechanisms. The Biochemical Journal 2012;441(1):61-76.
140. Flynn G, Chung I, Yu WD, Romano M, Modzelewski RA, Johnson CS, et al.Calcitriol (1, 25-dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosis. Oncology 2006;70(6):447-57.
141. Fortmann SP, Burda BU, Senger CA, Lin JS, Whitlock EP. Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: An updated systematic evidence review for the U.S. Preventive Services Task Force. Annals of Internal Medicine 2013;159(12):824-34.
142. Freedman DM, Looker AC, Chang SC, Graubard BI. Prospective study of serum vitamin D and cancer mortality in the United States. Jornal of the National Cancer Institute 2007;99(21):1594-602. [MEDLINE: 17971526]
143. Freedman DM, Looker AC, Abnet CC, Linet MS, Graubard BI. Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancr Research 2010;70(21):8587-97.
144. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer?. International Journal of Epidemiology 1980;9(3):227-31. [MEDLINE: 7440046]
145. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, et al.The role of vitamin D in cancer prevention. American Journal of Public Health 2006;96(2):252-61.
146. Garland CF, Gorham ED, Mohr SB, Grant WB, Giovannucci EL, Lipkin M, et al.Vitamin D and prevention of breast cancer: pooled analysis. The Journal of Steroid Biochemistry and Molecular Biology 2007;103(3-5):708-11. [MEDLINE: 17368188]
147. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes & Control 2005;16(2):83-95. [MEDLINE: 15868450]
148. Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al.Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2011, Issue 10. Art. No.: LIVER.
149. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. Journal of Clinical Oncology 2009;27(23):3757-63.
150. Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, et al.Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. American Journal of Preventive Medicine 2007;32(3):210-6. [MEDLINE: 17296473]
151. Guallar E, Miller ER 3rd, Ordovas JM, Stranges S. Vitamin D supplementation in the age of lost innocence. Annals of Internal Medicine 2010;152(5):327-9.
152. Guallar E, Stranges S, Mulrow C, Appel LJ, Miller ER 3rd. Enough is enough: Stop wasting money on vitamin and mineral supplements. Annals of Internal Medicine 2013;159(12):850-1.
153. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al.GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [PUBMED: 21195583]
154. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al.GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395-400. [PUBMED: 21194891]
155. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al.GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407-15. [PUBMED: 21247734]
156. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al.GRADE guidelines: 5. Rating the quality of evidence--publication bias. Journal of Clinical Epidemiology 2011;64(12):1277-82. [PUBMED: 21802904]
157. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al.GRADE guidelines 6. Rating the quality of evidence--imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93.
158. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al.GRADE guidelines: 7. Rating the quality of evidence--inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302. [PUBMED: 21803546]
159. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al.GRADE guidelines: 8. Rating the quality of evidence--indirectness. Journal of Clinical Epidemiology 2011;64(12):1303-10. [PUBMED: 21802903]
160. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al.GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology 2011;64(12):1311-6. [PUBMED: 21802902]
161. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al.GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013;66(2):151-7. [PUBMED: 22542023]
162. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al.GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158-72. [PUBMED: 22609141]
163. Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al.GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. Journal of Clinical Epidemiology 2013;66(2):173-83. [PUBMED: 23116689]
164. Hart PH, Gorman S, Finlay-Jones JJ. Modulation of the immune system by UV radiation: more than just the effects of vitamin D. National Review Immunology 2011;11(9):584-96.
165. Harvey NC, Cooper C. Vitamin D: some perspective please. BMJ 2012;345:e4695. [DOI: 10.1136/bmj.e4695]
166. Heaney RP, Recker RR, Grote J, Horst RL, Armas LA. Vitamin D(3) is more potent than vitamin D(2) in humans. Journal of Clinical Endocrinology and Metabolism 2011;96(3):E447-52.
167. Helzlsouer KJ, VDPP Steering Committee. Overview of the cohort consortium vitamin D pooling of rarer cancers. American Journal of Epidemiology 2010;172(1):4-9.
168. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58. [MEDLINE: 12111919]
169. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327(7414):557-60.
170. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
171. Hilger J, Friedel A, Herr R, Rausch T, Roos F, Wahl DA, et al.A systematic review of vitamin D status in populations worldwide. British Journal of Nutrition 2014;111(1):23-45.
172. Holick MF. Vitamin D deficiency. New England Journal of Medicine 2007;357(3):266-81. [MEDLINE: 17634462]
173. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al.Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology 2011;96(7):1911-30.
174. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319(7211):670-4.
175. Horst RL, Reinhardt TA, Satyanarayana Reddy G. Vitamin D metabolism. In: Feldman D, Wesley Pike J, Glorieux FH editor(s). Vitamin D. 2nd Edition. Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney, Tokyo: Elsevier Academic Press, 2005:15-36.
176. IARC. Vitamin D and Cancer. IARC Working Group Reports. Lyon, France: International Agency for Research on Cancer, 2008; Vol. 5.
177. International Committee on Harmonization. Code of Federal Regulations & Guidelines. Vol. 1, Philadelphia, US: Barnett International/PAREXEL, 1997.
178. World Health Organization. International Clinical Trials Registry Platform (ICTRP). www.who.int/ictrp/en/ 2011.
179. Ioannidis JP, Trikalinos TA, Zintzaras E. Extreme between-study homogeneity in meta-analyses could offer useful insights. Journal of Clinical Epidemiology 2006;59(10):1023-32.
180. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press, 2011.
181. Jakobsen JC, Gluud C. The necessity of randomized clinical trials. British Journal of Medicine & Medical Research 2013;3(4):1453-68.
182. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9. [MEDLINE: 11730399]
183. Krstic G. Re: "Circulating 25-hydroxyvitamin D and risk of pancreatic cancer". American Journal of Epidemiology 2011;173(4):476.
184. Krstic G. Vitamin D status vs. cancer survival/prognosis. Annals of Internal Medicine 2012;155:Comments on Chung et al. 2011 (Link: http://annals.org/article.aspx?articleid=1033222).
185. Kupferschmidt K. Uncertain verdict as vitamin D goes on trial. Science 2012;337(6101):1476-8.
186. Lamberg-Allardt C. Vitamin D in foods and as supplements. Progress in Biophysics and Molecular Biology 2006;92(1):33-8.
187. Lan KK, DeMets D. Discrete sequential monitoring boundaries for clinical trials. Biometrika 1983;70(3):659-63.
188. Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333(7568):597-600.
189. Lehmann U, Hirche F, Stangl GI, Hinz K, Westphal S, Dierkes J. Bioavailability of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial. The Journal of Endocrinology and Metabolism 2013;98(11):4339-45.
190. Leventis P, Kiely PD. The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency. Scandinavian Journal of Rheumatology 2009;38(2):149-53.
191. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al.The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration. PLoS Medicine 1999;6(7):1-28. [DOI: 10.1371/journal.pmed.1000100]
192. Lips P. Which circulating level of 25-hydroxyvitamin D is appropriate. Journal of Steroid Biochemistry and Molecular Biology 2004;89-90(1-5):611-4.
193. Lips P. Vitamin D physiology. Progress in Biophysics and Molecular Biology 2006;92(1):4-8.
194. Lips P. Worldwide status of vitamin D nutrition. The Journal of Steroid Biochemistry and Molecular Biology 2010;121(1-2):297-300.
195. Lips P. Interaction between vitamin D and calcium. Scandinavian Journal of Clinical and Laboratory Investigation 2012;72(243):60-4.
196. Logan VF, Gray AR, Peddie MC, Harper MJ, Houghton LA. Long-term vitamin D3 supplementation is more effective than vitamin D2 in maintaining serum 25-hydroxyvitamin D status over the winter months. British Journal of Nutrition 2013;109(6):1082-8.
197. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]
198. Marshall TG. Vitamin D discovery outpaces FDA decision making. Bioessays 2008;30(2):173-82. [MEDLINE: 18200565]
199. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine 2006; Vol. 3, issue 11:e442. [MEDLINE: 17132052]
200. McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials - A systematic review. JAMA 2003;289(19):2545-53.
201. Michos ED, Melamed ML. Vitamin D and cardiovascular disease risk. Current Opinion in Clinical Nutrition and Metabolic Care 2008;11(1):7-12. [MEDLINE: 18090651]
202. Moher D, Pham B, Jones A, Cook DJ, Jadad A, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis. Lancet 1998;352(9128):609-13. [MEDLINE: 9746022]
203. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354(9193):1896-900.
204. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Medicine 2009;6(7):e1000097.
205. Moyer VA, U.S. Preventive Services Task Force. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine 2013;158(9):691-6.
206. Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al.The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. Journal of Clinical Epidemiology 2013;66(7):736-42; quiz 742.e1-5. [PUBMED: 23623694]
207. Norman AW. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006;147(12):5542-8. [MEDLINE: 16946007]
208. Norman PE, Powell JT. Vitamin d and cardiovascular disease. Circulation Research 2014;114(2):379-93.
209. Ordóñez-Mena JM, Schöttker B, Haug U, Müller H, Köhrle J, Schomburg L, et al.Serum 25-hydroxyvitamin d and cancer risk in older adults: results from a large German prospective cohort study. Cancer Epidemiology, Biomarkers & Prevention 2013;22(5):905-16.
210. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD005633.pub2]
211. Patel VB, Vacek JL, Graves L, Bhattacharya RK. Calcium effects on vascular endpoints. Nutrition and Metabolism 2012;9(1):24.
212. Pilz S, Tomaschitz A, Obermayer-Pietsch B, Dobnig H, Pieber TR. Epidemiology of vitamin D insufficiency and cancer mortality. Anticancer Research 2009;29(9):3699-704.
213. Pilz S, Kienreich K, Tomaschitz A, Ritz E, Lerchbaum E, Obermayer-Pietsch B, et al.Vitamin D and cancer mortality: systematic review of prospective epidemiological studies. Anti-cancer Agents in Medicinal Chemistry 2013;13(1):107-17.
214. Pocock SJ. Clinical Trials: A Practical Approach. John Wiley & Sons, 2004.
215. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Controlled Clinical Trials 1997;18(6):580-93.
216. Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 1998;351(9095):47-52.
217. Redaniel MT, Gardner MP, Martin RM, Jeffreys M. The association of vitamin D supplementation with the risk of cancer in postmenopausal women. Cancer Causes & Control 2014;25(2):267-71.
218. Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 2014;383(9912):146-55.
219. Rejnmark L, Avenell A, Masud T, Anderson F, Meyer HE, Sanders KM, et al.Vitamin D with calcium reduces mortality: patient level pooled analysis of 70, 528 patients from eight major vitamin D trials. Journal of Clinical Endocrinology and Metabolism 2012;97(8):2670-81.
220. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
221. Romagnoli E, Mascia ML, Cipriani C, Fassino V, Mazzei F, D'Erasmo E, et al.Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. Journal of Clinical Endocrinology and Metabolism 2008;93(8):3015-20.
222. Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MB, Manson JE, et al.The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocrine Reviews 2012;33(3):456-92.
223. Savović J, Jones H, Altman D, Harris R, Juni P, Pildal J, et al.Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technology Assessment 2012;16(35):1-82.
224. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al.Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
225. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12. [: 7823387]
226. Schwartz GG, Skinner HG. Vitamin D status and cancer: new insights. Current Opinion in Clinical Nutrition and Metabolic Care 2007;10(1):6-11. [MEDLINE: 17143048]
227. Shiraki M, Fukuchi M, Kiriyama T, Okamoto S, Ueno T, Sakamoto H, et al.Alfacalcidol reduces accelerated bone turnover in elderly women with osteoporosis. Journal of Bone and Mineral Metabolism 2004;22(4):352-9.
228. Sperati F, Vici P, Maugeri-Saccà M, Stranges S, Santesso N, Mariani L, et al.Vitamin d supplementation and breast cancer prevention: a systematic review and meta-analysis of randomized clinical trials. PloS One 2013;8(7):e69269. [10.1371/journal.pone.0069269. Print 2013]
229. Stolzenberg-Solomon RZ, Vieth R, Azad A, Pietinen P, Taylor PR, Virtamo J, et al.A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Research 2006;66(20):10213-9.
230. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, Qi D, Patel AV, Helzlsouer KJ, et al.Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort consortium vitamin D pooling project of rarer cancers. American Journal of Epidemiology 2010;172(1):81-93.
231. Sutton ALM, MacDonald PN. Vitamin D: More than just a "Bone-a-Fide" hormone. Molecular Endocrynology 2003;17(5):777-91.
232. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al.Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses. International Journal of Epidemiology 2009;38(1):276-86.
233. Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, et al.The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis - a simulation study. PloS One 2011;6(10):e25491.
234. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User Manual for Trial Sequential Analysis (TSA). www.ctu.dk/tsa. (Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark, 2011) 2011.
235. Toner CD, Davis CD, Milner JA. The vitamin D and cancer conundrum: aiming at a moving target. Journal of the American Dietetic Association 2010;110(10):1492-500.
236. Trang HM, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. American Journal of Clinical Nutrition 1998;68(4):854-8.
237. Tripkovic L, Lambert H, Hart K, Smith CP, Bucca G, Penson S, et al.Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. American Journal of Clinical Nutrition 2012;95(6):1357-64.
238. Copenahgen Trial Unit. Trial Sequential Analysis, version 0.9. Copenahgen Trial Unit, 2011.
239. Tuohimaa P, Lou YR. Optimal serum calcidiol concentration for cancer prevention. Anticancer Research 2012;32(1):373-81.
240. Turner RM, Bird SM, Higgins JP. The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. PloS One 2013;8(3):e59202. [DOI: 10.1371/journal.pone.0059202]
241. Van Schoor NM, Lips P. Worldwide vitamin D status. Best Practice & Research. Clinical Endocrinology & Metabolism 2011;25(4):671-80.
242. Wesley Pike J, Shevde NK. The vitamin D receptor. In: Feldman D, Wesley Pike J, Glorieux FH editor(s). Vitamin D. 2nd Edition. Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney, Tokyo: Elsevier Academic Press, 2005:167-91.
243. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75. [MEDLINE: 18083463]
244. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86.
245. Woloszynska-Read A, Johnson CS, Trump DL. Vitamin D and cancer: clinical aspects. Best Practices & Research Clinical Endocrinology and Metabolism 2011;25(4):605-15.
246. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336(7644):601-5.
247. Yin L, Ordóñez-Mena JM, Chen T, Schöttker B, Arndt V, Brenner H. Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: a systematic review and meta-analysis. Preventive Medicine 2013;57(6):753-64.
248. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence. British Journal of Nutrition 2003;89(5):552-72. [MEDLINE: 12720576]
249. Zittermann A, Schleithoff SS, Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. British Journal of Nutrition 2005;94(4):483-92. [MEDLINE: 16197570]
250. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Progress in Biophysics and Molecular Biology 2006;92(1):39-48. [MEDLINE: 16600341]
251. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Gluud C. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD007469]